Therapeutic inhibition of miR-155 attenuates liver fibrosis via STAT3 signaling
Most chronic liver diseases progress to liver fibrosis, which, when left untreated, can lead to cirrhosis and hepatocellular carcinoma. MicroRNA (miRNA)-targeted therapeutics have become attractive approaches to treat diseases. In this study, we investigated the therapeutic effect of miR-155 inhibit...
Saved in:
Main Authors: | , , , , , , , , |
---|---|
Format: | Book |
Published: |
Elsevier,
2023-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000 am a22000003u 4500 | ||
---|---|---|---|
001 | doaj_d75412b366fa4f0f89a90a39beefcc68 | ||
042 | |a dc | ||
100 | 1 | 0 | |a Shashi Bala |e author |
700 | 1 | 0 | |a Yuan Zhuang |e author |
700 | 1 | 0 | |a Prashanth Thevkar Nagesh |e author |
700 | 1 | 0 | |a Donna Catalano |e author |
700 | 1 | 0 | |a Adam Zivny |e author |
700 | 1 | 0 | |a Yanbo Wang |e author |
700 | 1 | 0 | |a Jun Xie |e author |
700 | 1 | 0 | |a Guangping Gao |e author |
700 | 1 | 0 | |a Gyongyi Szabo |e author |
245 | 0 | 0 | |a Therapeutic inhibition of miR-155 attenuates liver fibrosis via STAT3 signaling |
260 | |b Elsevier, |c 2023-09-01T00:00:00Z. | ||
500 | |a 2162-2531 | ||
500 | |a 10.1016/j.omtn.2023.07.012 | ||
520 | |a Most chronic liver diseases progress to liver fibrosis, which, when left untreated, can lead to cirrhosis and hepatocellular carcinoma. MicroRNA (miRNA)-targeted therapeutics have become attractive approaches to treat diseases. In this study, we investigated the therapeutic effect of miR-155 inhibition in the bile duct ligation (BDL) mouse model of liver fibrosis and evaluated the role of miR-155 in chronic liver fibrosis using miR-155-deficient (miR-155 knockout [KO]) mice. We found increased hepatic miR-155 expression in patients with cirrhosis and in the BDL- and CCl4-induced mouse models of liver fibrosis. Liver fibrosis was significantly reduced in miR-155 KO mice after CCl4 administration or BDL. To assess the therapeutic potential of miR-155 inhibition, we administered an rAAV8-anti-miR-155 tough decoy in vivo that significantly reduced liver damage and fibrosis in BDL. BDL-induced protein levels of transforming growth factor β (TGF-β), p-SMAD2/3, and p-STAT3 were attenuated in anti-miR-155-treated compared with control mice. Hepatic stellate cells from miR-155 KO mice showed attenuation in activation and mesenchymal marker expression. In vitro, miR-155 gain- and loss-of-function studies revealed that miR-155 regulates activation of stellate cells partly via STAT3 signaling. Our study suggests that miR-155 is the key regulator of liver fibrosis and might be a potential therapeutic target to attenuate fibrosis progression. | ||
546 | |a EN | ||
690 | |a MT: Non-coding RNAs | ||
690 | |a anti-miR-155 tough decoy | ||
690 | |a SMAD2/3 | ||
690 | |a STAT3 | ||
690 | |a CCl4 | ||
690 | |a BDL | ||
690 | |a Therapeutics. Pharmacology | ||
690 | |a RM1-950 | ||
655 | 7 | |a article |2 local | |
786 | 0 | |n Molecular Therapy: Nucleic Acids, Vol 33, Iss , Pp 413-427 (2023) | |
787 | 0 | |n http://www.sciencedirect.com/science/article/pii/S2162253123001853 | |
787 | 0 | |n https://doaj.org/toc/2162-2531 | |
856 | 4 | 1 | |u https://doaj.org/article/d75412b366fa4f0f89a90a39beefcc68 |z Connect to this object online. |